{
  "main_header": {
    "sid": 302214,
    "name": "Beryl Drugs",
    "stock_name": "Beryl Drugs",
    "full_name": "Beryl Drugs Ltd",
    "name_url": "stocks-analysis/beryl-drugs",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "22.50",
    "chg": 0.56,
    "chgp": "2.55%",
    "dir": 1,
    "prev_price": "21.94",
    "mcapval": "11.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524606,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE415H01017",
    "curr_date": "Feb 03",
    "curr_time": "",
    "bse_nse_vol": "2.12 k",
    "exc_status": "Active",
    "traded_date": "Feb 03, 2026",
    "traded_date_str": "2026 02 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://uat-researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/beryl-drugs-302214-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Why is Beryl Drugs falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-beryl-drugs-fallingrising-3716008",
        "imagepath": "",
        "date": "2025-11-19 21:56:55",
        "description": "As of 19-Nov, Beryl Drugs Ltd is experiencing a decline in its stock price, currently at Rs 22.25, which represents a decrease of Rs 1.12 or 4.79%. The stock has been underperforming, having lost 7.64% over the last four days, and it is trading below all key moving averages, indicating a bearish trend. Additionally, the stock's delivery volume has significantly decreased by 94.66% compared to the 5-day average, suggesting a lack of investor interest. The stock has also shown poor performance over various time frames, with a year-to-date decline of 38.45%, further contributing to the negative sentiment surrounding it.\n\nIn the broader market context, Beryl Drugs' recent performance contrasts sharply with the Sensex, which has gained 0.85% over the past week and 9.02% year-to-date. This underperformance highlights the stock's struggles relative to the overall market, as it has consistently lagged behind the be..."
      },
      {
        "title": "Beryl Drugs Q2 FY26: Marginal Profit Recovery Amid Revenue Decline and Persistent Margin Pressures",
        "link": "https://www.marketsmojo.com/news/result-analysis/beryl-drugs-q2-fy26-marginal-profit-recovery-amid-revenue-decline-and-persistent-margin-pressures-3715858",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/BerylDrugs_quaterlyResult_3715858.png",
        "date": "2025-11-15 09:24:09",
        "description": "Beryl Drugs Limited, the Indore-based pharmaceutical formulations manufacturer, reported a marginal improvement in profitability for Q2 FY26, posting net profit of ₹0.01 crores compared to ₹0.02 crores in the previous quarter, though this represented a sharp decline from ₹0.01 crores in the year-ago period. With a micro-cap market capitalisation of just ₹12.00 crores and shares trading at ₹23.95, the company continues to grapple with fundamental challenges that have kept institutional investors at bay and prompted a cautious stance from analysts."
      },
      {
        "title": "How has been the historical performance of Beryl Drugs?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-beryl-drugs-3698943",
        "imagepath": "",
        "date": "2025-11-13 23:17:13",
        "description": "Answer:\nThe historical performance of Beryl Drugs shows a fluctuating trend in key financial metrics over the years.\n\nBreakdown:\nBeryl Drugs' net sales peaked at 26.89 Cr in Mar'23 but declined to 21.15 Cr by Mar'25. Other operating income increased from 0.00 Cr in Mar'19 to 1.41 Cr in Mar'25, contributing to a total operating income that reached a high of 27.16 Cr in Mar'23 before falling to 22.56 Cr in Mar'25. The raw material cost also saw a decline from 14.23 Cr in Mar'23 to 11.12 Cr in Mar'25, while total expenditure decreased from 24.95 Cr in Mar'23 to 19.91 Cr in Mar'25. Operating profit (PBDIT) slightly decreased from 2.68 Cr in Mar'24 to 2.65 Cr in Mar'25, with profit before tax showing a decline from 1.01 Cr in Mar'24 to 0.87 Cr in Mar'25. Profit after tax also decreased from 0.77 Cr in Mar'24 to 0.58 Cr in Mar'25. The company's total assets decreased from 17.39 Cr in Mar'23 to 15.95 Cr in Mar'25,..."
      }
    ],
    "total": 269,
    "sid": "302214",
    "stock_news_url": "https://uat-researchintel.adityabirlamoney.com/news/beryl-drugs-302214"
  },
  "announcements": [
    {
      "caption": "Board Meeting Intimation for To Consider And Approve The Unaudited Quarterly Financial Results For The Quarter Ended 31St December 2025",
      "datetime": "31-Jan-2026",
      "details": "Beryl Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/02/2026 inter alia to consider and approve 1. To consider and approve the date of holding EOGM for regularising the appointment of Mr. Shailendra Pathak as the Whole Time Director of the Company and fixing his role obligations and responsibilities and remuneration and for the appointment of Mrs. Neha Sarda as an Independent Director and for approval for material Related Party Transactions with M/s. Aminova Infusions P. Ltd. where Mr. Shailendra Pathak is a director holding 50% equity. 2. To consider and approve the Unaudited Quarterly Financial Results for the quarter ended 31st December 2025 3. To take on record the Limited Review Report by the Auditors for the quarter ended 31st December 2025",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Cessation",
      "datetime": "05-Jan-2026",
      "details": "RESIGNATION OF MRS. NEHA SHARMA COMPANY SECRETARY OF THE COMPANY W.E.F 3RD JANUARY 2026",
      "source": "BSE"
    },
    {
      "caption": "Appointment of Company Secretary and Compliance Officer",
      "datetime": "05-Jan-2026",
      "details": "APPOINTMENT OF MR. KAMLESH GUPTA AS COMPANY SECRETARY AND COMPLIANCE OFFICER OF THE COMPANY",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Why is Beryl Drugs falling/rising?

2025-11-19 21:56:55

As of 19-Nov, Beryl Drugs Ltd is experiencing a decline in its stock price, currently at Rs 22.25, which represents a decrease of Rs 1.12 or 4.79%. The stock has been underperforming, having lost 7.64% over the last four days, and it is trading below all key moving averages, indicating a bearish trend. Additionally, the stock's delivery volume has significantly decreased by 94.66% compared to the 5-day average, suggesting a lack of investor interest. The stock has also shown poor performance over various time frames, with a year-to-date decline of 38.45%, further contributing to the negative sentiment surrounding it. In the broader market context, Beryl Drugs' recent performance contrasts sharply with the Sensex, which has gained 0.85% over the past week and 9.02% year-to-date. This underperformance highlights the stock's struggles relative to the overall market, as it has consistently lagged behind the be...

Read More

Beryl Drugs Q2 FY26: Marginal Profit Recovery Amid Revenue Decline and Persistent Margin Pressures

2025-11-15 09:24:09

Beryl Drugs Limited, the Indore-based pharmaceutical formulations manufacturer, reported a marginal improvement in profitability for Q2 FY26, posting net profit of ₹0.01 crores compared to ₹0.02 crores in the previous quarter, though this represented a sharp decline from ₹0.01 crores in the year-ago period. With a micro-cap market capitalisation of just ₹12.00 crores and shares trading at ₹23.95, the company continues to grapple with fundamental challenges that have kept institutional investors at bay and prompted a cautious stance from analysts.

Read More

How has been the historical performance of Beryl Drugs?

2025-11-13 23:17:13

Answer: The historical performance of Beryl Drugs shows a fluctuating trend in key financial metrics over the years. Breakdown: Beryl Drugs' net sales peaked at 26.89 Cr in Mar'23 but declined to 21.15 Cr by Mar'25. Other operating income increased from 0.00 Cr in Mar'19 to 1.41 Cr in Mar'25, contributing to a total operating income that reached a high of 27.16 Cr in Mar'23 before falling to 22.56 Cr in Mar'25. The raw material cost also saw a decline from 14.23 Cr in Mar'23 to 11.12 Cr in Mar'25, while total expenditure decreased from 24.95 Cr in Mar'23 to 19.91 Cr in Mar'25. Operating profit (PBDIT) slightly decreased from 2.68 Cr in Mar'24 to 2.65 Cr in Mar'25, with profit before tax showing a decline from 1.01 Cr in Mar'24 to 0.87 Cr in Mar'25. Profit after tax also decreased from 0.77 Cr in Mar'24 to 0.58 Cr in Mar'25. The company's total assets decreased from 17.39 Cr in Mar'23 to 15.95 Cr in Mar'25,...

Read More

View All News